The
Food and Drug Administration notified Repros Therapeutics Inc. (Nasdaq:
RPRX) that additional information must be provided before a
pre-investigational new drug application meeting in November could be
held. Shares of the biopharmaceutical plummeted $4.01 to $6.50.
Repros Therapeutics must provide additional information
October 17, 2014 at 13:10 PM EDT
